Xin Gao and Wei-song Pan contributed equally to this work.
CARM1 activates myogenin gene via PCAF in the early differentiation of TPA-induced rhabdomyosarcoma-derived cells†
Article first published online: 8 MAR 2010
Copyright © 2010 Wiley-Liss, Inc.
Journal of Cellular Biochemistry
Volume 110, Issue 1, pages 162–170, 1 May 2010
How to Cite
Gao, X., Pan, W.-s., Dai, H., Zhang, Y., Wu, N.-h. and Shen, Y.-f. (2010), CARM1 activates myogenin gene via PCAF in the early differentiation of TPA-induced rhabdomyosarcoma-derived cells. J. Cell. Biochem., 110: 162–170. doi: 10.1002/jcb.22522
- Issue published online: 16 APR 2010
- Article first published online: 8 MAR 2010
- Manuscript Accepted: 7 JAN 2010
- Manuscript Received: 23 APR 2009
- National Natural Science Foundation of China. Grant Numbers: 90919048, 30721063
- National Basic Research Program of China. Grant Number: 2005CB522405
- Special Funds of State Key Laboratories. Grant Number: 2060204
- RD cells
CARM1/PRMT4 is a member of the protein arginine methyltransferase (PRMT) family. CARM1 as a transcriptional coactivator plays an active role on mammalian genes. Here, we show that CARM1 can be recruited to the promoter of myogenin gene to enhance its transcriptional activation via PCAF at the early stage of TPA-induced RD cell differentiation. By adding adenosine dialdehyde, AdOx, to inhibit the PRMT in RD cells, the TPA-induced recruiting of p300, PCAF and the Brg1 at the myogenin promoter is abolished and myogenic differentiation is blocked. More specifically, the expression of PCAF and its nucleation are prohibited when CARM1 is knockdown by its specific siRNA. We suggest that the physical interaction of CARM1 and PCAF is likely pivotal for the activation of PCAF in the downstream of CARM1 pathway for inducing myogenin under TPA-induced differentiation. The findings shed lights on novel therapeutic targets in the treatment of rhabdomyosarcoma patients. J. Cell. Biochem. 110: 162–170, 2010. © 2010 Wiley-Liss, Inc.